Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | Venetoclax |
Trade Name | Venclexta |
Synonyms | ABT-199|RG7601|GDC-0199|ABT119|Venclyxto |
Drug Descriptions |
Venclexta (venetoclax) is a BH3-mimetic that binds to and inhibits BCL2, resulting in increased tumor cell apoptosis (PMID: 26589495, PMID: 25048785). Venclexta (venetoclax) is FDA approved for use in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), and in combination with chemotherapy in patients 75 years old or older with newly-diagnosed acute myeloid leukemia (FDA.gov). |
DrugClasses | BCL2 inhibitor 27 |
CAS Registry Number | 1257044-40-8 |
NCIT ID | C103147 |